Literature DB >> 29678828

Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.

Md Kamrul Hasan1, Jian Yu1, George F Widhopf1, Laura Z Rassenti1, Liguang Chen1, Zhouxin Shen2, Steven P Briggs2, Donna S Neuberg3, Thomas J Kipps1.   

Abstract

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic protein expressed on chronic lymphocytic leukemia (CLL) that can serve as a receptor for Wnt5a, which can promote leukemia cell migration, proliferation, and survival. We found Wnt5a could induce ROR1 to complex with DOCK2 (dedicator of cytokinesis 2) and induce activation of Rac1/2; these effects could be blocked by cirmtuzumab, a humanized anti-ROR1 monoclonal antibody. We find that silencing DOCK2 specifically impaired the capacity of Wnt5a to induce activation of Rac1/2 or enhance CLL cell proliferation. We generated truncated forms of ROR1 and found the cytoplasmic proline-rich domain (PRD) of ROR1 was required for Wnt5a to induce ROR1 to complex with DOCK2 and activate Rac1/2 in the CLL cell-line MEC1. We introduced single amino acid substitutions of proline (P) to alanine (A) in the ROR1-PRD at potential binding sites for the Src-homology 3 domain of DOCK2. In contrast to wild-type ROR1, or other ROR1 P→A variants, ROR1P808A was unable to recruit DOCK2 in response to Wnt5a. Moreover, unlike MEC1 cells transfected with wild-type ROR1 or ROR1 with P→A substitutions at positions 784, 826, or 841, MEC1 cells transfected to express ROR1P808A did not have a growth advantage over MEC1 cells that do not express ROR1. This study reveals that the recruitment of DOCK2 may be critical for the capacity of Wnt5a to enhance CLL proliferation, which may contribute to the observed increased tendency for disease progression in patients who have CLL cells that express high levels of ROR1.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29678828      PMCID: PMC6043980          DOI: 10.1182/blood-2017-12-819383

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  37 in total

1.  MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation.

Authors:  A Stacchini; M Aragno; A Vallario; A Alfarano; P Circosta; D Gottardi; A Faldella; G Rege-Cambrin; U Thunberg; K Nilsson; F Caligaris-Cappio
Journal:  Leuk Res       Date:  1999-02       Impact factor: 3.156

Review 2.  Rho GTPases in cell biology.

Authors:  Sandrine Etienne-Manneville; Alan Hall
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

3.  Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity.

Authors:  Jean-François Côté; Kristiina Vuori
Journal:  J Cell Sci       Date:  2002-12-15       Impact factor: 5.285

4.  DOCK2 regulates Rac activation and cytoskeletal reorganization through interaction with ELMO1.

Authors:  Terukazu Sanui; Ayumi Inayoshi; Mayuko Noda; Eiko Iwata; Jens V Stein; Takehiko Sasazuki; Yoshinori Fukui
Journal:  Blood       Date:  2003-06-26       Impact factor: 22.113

5.  ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia.

Authors:  H Elizabeth Broome; Laura Z Rassenti; Huan-You Wang; Lilly M Meyer; Thomas J Kipps
Journal:  Leuk Res       Date:  2011-08-02       Impact factor: 3.156

Review 6.  Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.

Authors:  Michael Y Choi; George F Widhopf; Christina C N Wu; Bing Cui; Fitzgerald Lao; Anil Sadarangani; Joy Cavagnaro; Charles Prussak; Dennis A Carson; Catriona Jamieson; Thomas J Kipps
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

7.  Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo.

Authors:  Amitava Sengupta; Jorden Arnett; Susan Dunn; David A Williams; Jose A Cancelas
Journal:  Blood       Date:  2010-04-20       Impact factor: 22.113

Review 8.  Rho GTPases in cancer cell biology.

Authors:  Francisco M Vega; Anne J Ridley
Journal:  FEBS Lett       Date:  2008-05-05       Impact factor: 4.124

9.  Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

Authors:  Sivasubramanian Baskar; Ka Yin Kwong; Thomas Hofer; Jessica M Levy; Michael G Kennedy; Elinor Lee; Louis M Staudt; Wyndham H Wilson; Adrian Wiestner; Christoph Rader
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

10.  DOCK2 is a Rac activator that regulates motility and polarity during neutrophil chemotaxis.

Authors:  Yuya Kunisaki; Akihiko Nishikimi; Yoshihiko Tanaka; Ryosuke Takii; Mayuko Noda; Ayumi Inayoshi; Ken-ichi Watanabe; Fumiyuki Sanematsu; Takehiko Sasazuki; Takehiko Sasaki; Yoshinori Fukui
Journal:  J Cell Biol       Date:  2006-08-28       Impact factor: 10.539

View more
  18 in total

1.  Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Authors:  Michael Y Choi; George F Widhopf; Emanuela M Ghia; Reilly L Kidwell; Md Kamrul Hasan; Jian Yu; Laura Z Rassenti; Liguang Chen; Yun Chen; Emily Pittman; Minya Pu; Karen Messer; Charles E Prussak; Januario E Castro; Catriona Jamieson; Thomas J Kipps
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

2.  STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Alessandra Ferrajoli; Jan A Burger; Prithviraj Bose; Phillip A Thompson; Nitin Jain; William G Wierda; Orit Uziel; Michael J Keating; Zeev Estrov
Journal:  J Immunol       Date:  2019-10-23       Impact factor: 5.422

3.  Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.

Authors:  Yun Chen; Liguang Chen; Jian Yu; Emanuela M Ghia; Michael Y Choi; Ling Zhang; Suping Zhang; Elsa Sanchez-Lopez; George F Widhopf; Karen Messer; Laura Z Rassenti; Catriona Jamieson; Thomas J Kipps
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

4.  Hypermethylation of DMTN promotes the metastasis of colorectal cancer cells by regulating the actin cytoskeleton through Rac1 signaling activation.

Authors:  Ya-Ping Ye; Hong-Li Jiao; Shu-Yang Wang; Zhi-Yuan Xiao; Dan Zhang; Jun-Feng Qiu; Ling-Jie Zhang; Ya-Li Zhao; Ting-Ting Li; Wen-Ting Liao; Yan-Qing Ding
Journal:  J Exp Clin Cancer Res       Date:  2018-12-04

5.  ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer.

Authors:  Gaurav Pandey; Nicholas Borcherding; Ryan Kolb; Paige Kluz; Wei Li; Sonia Sugg; Jun Zhang; Dazhi A Lai; Weizhou Zhang
Journal:  Cancers (Basel)       Date:  2019-05-24       Impact factor: 6.575

6.  Leukemia multiclass assessment and classification from Microarray and RNA-seq technologies integration at gene expression level.

Authors:  Daniel Castillo; Juan Manuel Galvez; Luis J Herrera; Fernando Rojas; Olga Valenzuela; Octavio Caba; Jose Prados; Ignacio Rojas
Journal:  PLoS One       Date:  2019-02-12       Impact factor: 3.240

7.  PITPNA-AS1 abrogates the inhibition of miR-876-5p on WNT5A to facilitate hepatocellular carcinoma progression.

Authors:  Jianmin Sun; Yubao Zhang; Bing Li; Yuandi Dong; Chengming Sun; Fang Zhang; Li Jin; Dongqin Chen; Wansheng Wang
Journal:  Cell Death Dis       Date:  2019-11-07       Impact factor: 8.469

Review 8.  Targeting Rac and Cdc42 GEFs in Metastatic Cancer.

Authors:  Maria Del Mar Maldonado; Julia Isabel Medina; Luis Velazquez; Suranganie Dharmawardhane
Journal:  Front Cell Dev Biol       Date:  2020-04-08

Review 9.  The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention.

Authors:  Kerstin Menck; Saskia Heinrichs; Cornelia Baden; Annalen Bleckmann
Journal:  Cells       Date:  2021-01-12       Impact factor: 6.600

10.  Two cancer stem cell-targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model.

Authors:  Ingrid W Caras
Journal:  Stem Cells Transl Med       Date:  2020-04-12       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.